Yazarlar : Gattermann N, Finelli C, Della Porta M, et al

Yayın : Haematologica.

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22419577

Konu : MDS

Literatür İçeriği :  

Abstract

Background. Reductions in transfusion requirements/improvements in hematologic parameters have been associated with iron chelation therapy in transfusion-dependent patients, including those with myelodysplastic syndromes; these data have been limited to case reports/small studies. Design and Methods. To explore this observation in a large patient population, we report a post-hoc analysis evaluating hematologic response to deferasirox in a cohort of iron-overloaded myelodysplastic syndromes patients enrolled in the Evaluation of Patients' Iron Chelation with Exjade® (EPIC) study using International Working Group 2006 criteria. Results. 247, 100 and 50 patients without concomitant myelodysplastic syndromes medication were eligible for erythroid, platelet and neutrophil response analyses. Erythroid, platelet and neutrophil responses were observed in 21.5% (53/247), 13.0% (13/100) and 22.0% (11/50) of patients after a median of 109, 169 and 226 days, respectively. Median serum ferritin reductions were greater in hematologic responders compared with non-responders at end of study, although these differences were not statistically significant. Reduction in labile plasma iron to <0.4 μmol/L was observed from week 12 onwards; this change did not differ between hematologic responders and non-responders. Conclusions. This analysis suggests that deferasirox treatment for up to 1 year could lead to improvement in hematologic parameters in some patients with myelodysplastic syndromes.

Literatür Arşivi